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Chromosome 22q11.2 deletion is the most common chromosomal alteration associated with
DiGeorge syndrome (DGS), even though this is not the only underlying cause of DGS. In rare
patients, mutations in a single gene, TBX1, have been described resulting in a DGS phenotype.
Recently, it has been reported that at least part of the TBX1 mutant phenotype is due to
excessive bone morphogenetic proteins (BMP) signaling. Evidence suggests that miRNA may
modulate the expression of critical T-box transcriptional regulators during midface develop-
ment and Bmp-signaling. We report on a 7-year-old Caucasian male born to a mother affected
with gestational diabetes (GDM) who had a 371Kb-interstitial deletion of 3p12.3 identified by
array CGH, involving the ZNF717, MIR1243, and 4273 genes. The child presented with a
DiGeorge anomaly (DGA) associated with unilateral renal agenesis and language delay. The
immunological evaluation revealed a severe reduction and impairment of T lymphocytes. FISH
analysis and TBX1 sequencing were negative. Among the miRNA-4273 predicted target genes,
we found BMP3, which is involved in several steps of embryogenesis including kidney and lung
organogenesis and in insulin geneexpression. Since,DGA isnot commonly found innewbornsof
diabetic mothers, we hypothesize that the pathogenesis of DGA associated with GDM is
multifactorial, involving both genetic and/or epigenetic cofactors.
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1 | INTRODUCTION
DiGeorge syndrome (DGS), also known as 22q11.2 deletion syndrome
(22q11.2 DS) was first described in the 1960s and classically comprises
facial anomalies, hypoparathyroidism, cardiac malformations, develop-
mental, and speech delay, and mild to moderate immune deficiency
related to thymic a/hypoplasia (Cancrini et al., 2014). Chromosome
22q11.2 deletion is the most common chromosomal alteration
associated with DGS, occurring in approximately 1:4,000 live births
(Cirillo et al., 2014; Tezenas Du Montcel, Mendizabai, Ayme, Levy, &
Philip, 1996). However, a small number of patients affected with other
genetic syndromes share a few clinical features with the 22q11
spectrum, including Opitz G/BBB (McDonald-MCGinn et al., 1995;
Robin, Opitz, & Muenke, 1996) and CHARGE syndrome (Devriendt,
Fryns, Mortier, van Thienen, & Keymolen, 1998), and other chromo-
somal deletions as 16p11.2, 10p13, 17p13, 4q34.1q35.2 (Ballif et al.,
2007; Cuturilo et al., 2011; Greenberg, Elder, Haffner, Northrup, &
Ledbetter, 1988; Pignata et al., 1996).
Teratogenic influences such as maternal diabetes (Wilson et al.,
1993) or prenatal exposure to retinoic acid or alcoholmay also lead to a
DiGeorge anomaly (DGA). However, only a minority of newborns of
diabetic mothers have a DGA, thus implying the requirement for
multiple factors for the expression of this anomaly. In rare patients
with a DGS phenotype but without the 22q11.2 deletion, mutations in
the single T-box (TBX1) gene, which plays an important role in
regulating the expression of several transcription factors, have been
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described (Yagi et al., 2003). However, in some patients with a
presumed diagnosis of DGS, the underlying etiology cannot be
identified (Rope, Cragun, Saal, & Hopkin, 2009). Chromosomal
microarray analysis has been advocated as a first-line diagnostic
approach for patients with multiple congenital anomalies, including
patients with a phenotype suggestive of 22q11.2 DS and normal
fluorescent in situ hybridization (FISH) (Busse et al., 2010).
We report on a child born to a mother with gestational diabetes
mellitus (GDM) affected with a DGA, associated with a 3p12.3
deletion, involving the ZNF717,MIR1243, and 4273 genes, which have
a role in the regulation of embryogenesis. Among the miRNA-4273
predicted target genes, there is the bone morphogenetic protein-3
(BMP3), which is involved in several steps of embryogenesis, including
kidney and lung. We hypothesize that this alteration may act as a
genetic cofactor in favoring the clinical expression of the DGA in
newborns of diabetic mothers.
2 | CLINICAL REPORT
The proband is a 7-year-old Caucasian male referred to our
Immunodeficiency Center at the age of 25 months because of
recurrent upper respiratory infections (URIs), hypoparathyroidism,
unilateral renal agenesis diagnosed during fetal life and language delay.
He was the third child of non-consanguineous parents. The family
history was unremarkable except for a maternal aunt, affected with
type 2 diabetes, who died of kidney cancer, and the paternal
grandfather who was affected with coronary artery disease. No
further chronic or genetic diseases were reported in other family
members. The proband was born to a 36-year-old female with GDM
after a 36 week gestation. Delivery was by caesarean section. The
mother has had GDM with each of her previous two pregnancies;
during this pregnancy, she took subcutaneous insulin twice daily,
monitored blood sugar four times per day, and deniedworsening of her
hyperglycemia during the pregnancy. There was no exposure to
alcohol, tobacco, or other teratogenic factors. No additional health
problems such as hypertension, obesity, or type 2 diabetes were
reported in the mother. Fetal movements were reported as normal.
The birth weight was 4.2 kg (>90th centile). The child had a short
period of hypoglycemia and received a glucose infusion. He was
discharged on the third day of life. On the fourth day of life he was re-
admitted due to hyperbilirubinemia and tremors of the upper and
lower right limbs. Serum calcium levels were 5.2mg/dl (normal value:
9–11mg/dl) and the electrolytes were normal. Therapy with calcium
and alpha-calcidiol was successfully started. An echocardiogram
showed a patent oval foramen. Cerebral ultrasonography revealed a
cyst of the septum pellucidum.
At 24 months, growth and head circumference were normal.
Dysmorphic features included long face, a small nose with a normal
bridge, long philtrum, highly arched palate, and dental enamel
dysplasia (Figure 1a,b). No other craniofacial findings such as, bulbous
nasal tip and prominent nasal root, hypoplastic alae nasae, hooded
eyelids, cupped and protuberant ears, preauricular pits or tags, or
craniosynostosis, which are frequently reported in children with
22q11.2DS, were detected in the patient.
The chest and abdominal examination was normal. A speech delay
was observed during the first years of life. At the age of 4 years,
expressive language was characterized by a sporadic use of short
sentences consisting of 2–3 words, with oculomotor difficulties and
abnormalities of perceptual organization. The language impairment
was associated with an inhibited temperament and signs of anxiety.
However, comprehensive language was appropriate for age. Psycho-
motor development assessed byGriffithMental Developmental Scale-
Extended Revised (GMDS-ER) was normal (IQ = 86). The patient
received psychomotor and speech therapy, resulting in a progressive
improvement of the expressive language, even though it remained
poorly structured.
Since, the age of 15 months, the patient had recurrent and
frequent episodes of URIs. The ear-nose-throat evaluation did not
reveal any hearing loss. Ophthalmologic examination was normal. G-
banded chromosomal analysis on peripheral blood lymphocytes
indicated a normal karyotype.
Fluorescent in situ hybridization performed to exclude a 22q11.2
deletion syndrome and TBX1 sequencing were both negative.
3 | METHODOLOGY AND RESULTS
3.1 | Cytogenetic and molecular genetics
A 4 × 44 CytoChip™ array with ISCA design (BlueGnome Ltd;
Cambridge, UK) was used in accordance with manufacturer’s
guidelines for genome screening. The arrays were scanned using
the InnoScan 710 and analyzed using BlueFuse for Microarrays 3.5
software (BlueGnome, Cambridge, UK), referring to Hg19 Genome
Assembly (NCBI Build GRCh37). Copy number variants were
classified according to the Database of Genomic Variants, the
DECIPHER Database and the UCSC Genome Browser. Oligo-array
CGH analysis identified a 3p12.3 deletion, spanning approximately
317 kb (Figure 2) and overlaps three genes (LOC401074, ZNF717,
FLJ20518), MIR1243, and MIR4273 (National Center for Biotech-
nology Information, hg19). The result, according to the ISCN
nomenclature, is: arr [hg19] (75, 571, 183–75, 888, 573 × 1).
The miRBase database available online at http://microrna.sanger.
ac.uk/ which provides integrated information about miRNAs and
related predicted genes targets, was used to identify the potential
genetic targets of the deleted miRNAs. The potential effects of the
reduced dosage of the deleted miRNAs on gene targets were
considered during the analysis. Among the miRNA-4273 predicted
target genes, there are several genes, such as BMP3, which are
involved in several steps of embryogenesis, such as kidney and lung
organogenesis and in insulin gene expression.
3.2 | Immunological evaluation
Initial immunological evaluation revealed leukopenia (median white
blood cell count ± SD 4900 ± 1237 cells/μl; range over the time
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3780–7470) with moderate lymphopenia (median 2577 ± 662
cells/μl; range 1170–2670), as illustrated in Table 1. At the diagnosis,
the flow cytometric analysis of peripheral blood mononuclear cells
(PBMCs) revealed a TlowB +NK+ combined immunodeficiency (CID),
characterized by a marked reduction of CD3+ (373 cell/μl), CD4+
(163 cells/μl), and CD8+ (140 cells/μl) T cells. B lymphocytes were
increased (1352 cells/μl), while CD56+ were normal. In order to
further investigate the T-cell phenotype and function in the context of
a putative thymic a/hypoplasia, we evaluated the naive and memory
subsets and the proliferative response to mitogens. As observed in
Figure 3, among CD3 + CD4 + T cells, a severe reduction of naïve CD45
RA+ T cells and a prevalence of memory CD45RO+CD4+ T cells were
evident. On the contrary, although the number of CD3 +CD8+ T cells
was lower than age-matched controls, the distribution of the naïve and
memory phenotypes was normal. A reduction of CD4 + CD25+, which
include Treg cells, paralleled the CD4+ lymphopenia. The proliferative
response to phytohemagglutinin (PHA) and pockweed, evaluated by
thymidineuptake fromcultured cells pulsedwith0.5 μCi [3H] thymidine
(Amersham International), was decreased, corresponding to the 45%
and 39% of the control, respectively.
FIGURE 1 Proband’s phenotype. a: Noted long face, long philtrum, and small nose with a normal bridge. b: Highlyarched palate and dental
enamel dysplasia. [Colour figure can be viewed at wileyonlinelibrary.com]
FIGURE 2 The ideogram of chromosome 3. The red bar indicates the deletion of the 3p12.3 region identified in our patient. [Colour figure
can be viewed at wileyonlinelibrary.com]
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During the 5 years of follow-up, despite a sporadicmild increase in
the lymphocytes count at 3 years of age, a progressive further
reduction of lymphocytes was documented.
Even though TCR αβ cells predominated, an increased number of
TCR γδ T cells (20%), was detected at the age of 6 years. However,
despite the marked reduction of T cells, the patient did not suffer from
severe episodes of bacteremia, systemic C. albicans infections, or
other opportunistic and life-threatening infections. Furthermore, a
normalization of the proliferative response to mitogens was observed
at 3 years.
TABLE 1 Immunological evaluation during the long term follow-up
Age (y) 2 2.6 3 4.6 5 6
Serum Ig (mg/dl)
IgG 605 ND 809 684 936 800
IgA 70.9 ND 94.3 51.7 94.7 91.6
IgM 85.4 ND 188 98 130 94
Leukocytes
(cells/mm3)
5800 4100 7470 4000 4200 5160
Lymphocytes
(cells/mm3)
2330 1320 2670 1590 1170 1370
T cells (CD3+) 373 (2100–6200) 396 (1400–3700) 881 (1400–3700) 700 (1400–3700) 526 (1400–3700) 698 (1400–3700)
CD3 + CD4+ 163 (1300–3400) 198 (700–2200) 454 (700–2200) 318 (700–2200) 246 (700–2200) 233 (700–2200)
CD3 + CD8+ 140 (620–2000) 145 (490–1300) 267 (490–1300) 366 (490–1300) 164 (490–1300) 192 (490–1300)
CD19 1351 (720–2600) 436 (1400–3700) 854 (1400–3700) 397 (1400–3700) 304 (1400–3700) 110 (1400–3700)
CD56 419 (180–920) 396 (130–720) 667 (130–720) ND 316 (130–720) 507 (130–720)
CD4 + CD25 +% 1 ND ND ND ND 1
TCRαβ% 31
TCRγδ% 20
The brackets indicate normal values for age; ND, not done.
FIGURE 3 Blood T cell subsets by flow cytometry at the age of two years. a: Naïve T cells (CD45RA +) represent the 32% of the CD4+ cells.
b: Memory T cells (CD45RO +) represent the 70% of the CD4+ T cells. c, d: Normal distribution of the naïve and memory CD8+ T cells
[Colour figure can be viewed at wileyonlinelibrary.com]
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Despite consistently normal serum levels of IgM, IgG IgA, and IgE,
the patient had an absent antibody specific production toward
Hepatitis B. Autoantibodies to anti-thyroglobulin (TGB-Ab),
anti-thyroid peroxidase (TPO-Ab), anti-nuclear (ANA), anti-double
stranded DNA (dsDNA), and anti-transglutaminase were all negative.
4 | DISCUSSION
In this study, we report a novel association between a DGA
characterized by a quantitative and qualitative immunodeficiency
resembling a TlowB +NK+ combined immunodeficiency in a child with
a 3p12.3 deletion born to a mother with GDM.
Diabetic embryopathy encompasses a wide spectrum of congeni-
tal anomalies with a multifactorial pathogenesis (Castori, 2013).
Holoprosencephaly, caudal dysgenesis, VACTERL association, and
cardiovascular congenital abnormalities are the most common
features associated with diabetic embryopathy. Furthermore, renal
dysgenesis has been frequently reported in newborns of diabetic
mothers. Moreover, DGA has also been reported in newborns of
diabetic mothers (Dentici et al., 2013; Novak, Robert, & Robinson,
2005). In these patients, unilateral o bilateral renal agenesis has also
been found, suggesting a non-random association between the two
events.
To date, cytogenetic studies in patients with DGA born to diabetic
mothers have either not been done or have failed to identify an
underlying genetic alteration.
The etiology of diabetic embryopathy is multifactorial and
results from the interplay between uterine microenvironment,
parental and offspring genomes, and epigenetic regulation (Castori,
2013; Vrachnis et al., 2012). It has been hypothesized that
alterations of the metabolic homeostasis associated with DM could
profoundly affect several signal transduction pathways and mor-
phogenetic processes (Castori, 2013), thus resulting in developmen-
tal field defects. Altered expression of developmental control genes,
as Pax3, has been reported in mouse models of diabetic
embryopathy. However, a molecular mechanism underlying the
phenotypic spectrum of DM-associated structural anomalies in
humans has not been reported yet. Of note, even though several
studies documented a high teratogenic potential for women with
pre-gestational DM type 1 (DM1) or 2 (DM2), pregnant women
developing GDM have an overall very low risk for fetal congenital
anomalies, suggesting the requirement of further pathogenetic co-
factors (Balsells, Garcia-Patterson, Gich, & Corcoy, 2012). In our
study, we found a novel interstitial deletion at 3p12.3 encompassing
three genes, ZNF717, MIR1243 and MIR4273 in a patient with
multiple congenital anomalies born to a mother whose pregnancy
was complicated by GDM. MiRNAs are a family of small, non-coding
RNAs that modulate gene expression by targeting messenger RNAs
for degradation, translational repression or both. MiRNAs may affect
a wide range of biological responses including proliferation,
differentiation, apoptosis and cell metabolism, and are implicated
in several processes, such as brain differentiation and function,
growth, and skeletal and cardiovascular development. Individual
miRNAs can target multiple messenger RNAs, controlling the
expression of several genes, and frequently their alterations can
have a profound impact on cellular development and function
(Zhang, Wang, & Gameinhart, 2013). Furthermore, there is evidence
for miRNA dysregulation and biogenesis having a role in the
immunological, cardiac, endocrinological, and neurological pheno-
type of patients with 22q11.2 DS due to DiGeorge Critical Region
Gene 8 (DGCR8) haploinsufficiency (de la Morena et al., 2013).
DGCR8 encodes a component of the microprocessor complex
involved in miRNA biogenesis, which is deleted in the majority
of patients with 22q11.2DS (Sellier et al., 2014). Furthermore, it has
been recently demonstrated that the haploinsufficiency of
miRNA-17–92 due to a germline hemizygous deletion of MIR17HG
is responsible for several developmental abnormalities observed in
some patients with microcephaly, short stature, and digital
abnormalities (De Pontual et al., 2012).
Evidence also indicates that miRNAs may modulate the
expression of critical T-box transcriptional regulators during midface
development and the BMPs. Part of the TBX1 mutant phenotype is
due to excessive Bmp-signaling (Wang et al., 2013). Interestingly,
BMP3, a member of the transforming growth factor β superfamily,
which plays a key role during embryogenesis, and in particular, in the
development of the organs that require an epithelial-mesenchymal
interaction (such as the thymus and kidney) is among the
miRNA-4273 predicted target genes (Takahashi & Ikeda, 1996).
More recently, it has been reported that BMP3 has a role in the
regulation of insulin gene expression in pancreatic beta-cells as well
(Bonner et al., 2011). However, a clear causative relationship
between haploinsufficiency of ZNF717 and the patient’s clinical
phenotype was not found.
In conclusion, we report for the first time on the association
between a DGA in an infant born to a mother with GDM and a
microdeletion of chromosome 3, involving the MIR4273 gene. Even
though the causal relationship between the two events remains to be
proven, our report provides further support for the multifactorial
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